BioCryst Pharmaceuticals (BCRX) Competitors $8.43 +0.08 (+0.90%) As of 10:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCRX vs. RGEN, IONS, MDGL, ALKS, LGND, FOLD, CLDX, DVAX, MNKD, and NVAXShould you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Repligen (RGEN), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), MannKind (MNKD), and Novavax (NVAX). These companies are all part of the "biotechnology" industry. BioCryst Pharmaceuticals vs. Its Competitors Repligen Ionis Pharmaceuticals Madrigal Pharmaceuticals Alkermes Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics Dynavax Technologies MannKind Novavax Repligen (NASDAQ:RGEN) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership. Do insiders and institutionals hold more shares of RGEN or BCRX? 97.6% of Repligen shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 1.2% of Repligen shares are held by insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is RGEN or BCRX more profitable? Repligen has a net margin of -2.05% compared to BioCryst Pharmaceuticals' net margin of -6.41%. Repligen's return on equity of 4.65% beat BioCryst Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Repligen-2.05% 4.65% 3.26% BioCryst Pharmaceuticals -6.41%N/A -1.78% Do analysts recommend RGEN or BCRX? Repligen presently has a consensus target price of $169.45, suggesting a potential upside of 50.45%. BioCryst Pharmaceuticals has a consensus target price of $16.70, suggesting a potential upside of 98.22%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Which has better valuation & earnings, RGEN or BCRX? Repligen has higher revenue and earnings than BioCryst Pharmaceuticals. Repligen is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$673.96M9.39-$25.51M-$0.25-450.54BioCryst Pharmaceuticals$450.71M3.91-$88.88M-$0.18-46.81 Which has more volatility & risk, RGEN or BCRX? Repligen has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Does the media prefer RGEN or BCRX? In the previous week, BioCryst Pharmaceuticals had 20 more articles in the media than Repligen. MarketBeat recorded 36 mentions for BioCryst Pharmaceuticals and 16 mentions for Repligen. Repligen's average media sentiment score of 0.75 beat BioCryst Pharmaceuticals' score of 0.64 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 9 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryRepligen and BioCryst Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCRX vs. The Competition Export to ExcelMetricBioCryst PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.77B$2.42B$5.46B$9.64BDividend YieldN/A1.78%3.99%4.14%P/E Ratio-46.8819.7130.0125.17Price / Sales3.91426.05372.2177.01Price / CashN/A165.0335.9458.58Price / Book-4.194.158.155.69Net Income-$88.88M$31.61M$3.26B$265.48M7 Day Performance5.97%0.76%1.05%2.60%1 Month Performance-4.15%2.86%2.75%1.95%1 Year Performance5.71%4.14%28.06%23.97% BioCryst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCRXBioCryst Pharmaceuticals4.1685 of 5 stars$8.43+0.9%$16.70+98.2%+12.2%$1.77B$450.71M-46.88530Earnings ReportAnalyst RevisionRGENRepligen4.7759 of 5 stars$119.65-1.7%$169.92+42.0%-30.1%$6.72B$634.44M-265.891,778IONSIonis Pharmaceuticals4.4986 of 5 stars$41.17-2.5%$55.67+35.2%-12.3%$6.55B$705M-13.771,069Insider TradeAnalyst RevisionMDGLMadrigal Pharmaceuticals4.3861 of 5 stars$294.16-1.4%$420.63+43.0%+46.2%$6.53B$317.38M-16.3090Positive NewsEarnings ReportAnalyst ForecastAnalyst RevisionALKSAlkermes4.7847 of 5 stars$26.15+0.1%$40.92+56.5%+0.6%$4.31B$1.56B12.511,800Positive NewsLGNDLigand Pharmaceuticals3.5201 of 5 stars$134.92-0.7%$147.17+9.1%+56.8%$2.60B$167.13M-18.9580News CoveragePositive NewsFOLDAmicus Therapeutics4.1132 of 5 stars$6.12+1.0%$16.22+165.1%-32.1%$1.88B$528.29M-67.99480CLDXCelldex Therapeutics1.3835 of 5 stars$22.01-5.7%$50.11+127.7%-33.8%$1.46B$7.02M-8.15150Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionDVAXDynavax Technologies4.3083 of 5 stars$11.29-0.6%$24.00+112.6%+2.9%$1.36B$277.25M-21.71350News CoveragePositive NewsEarnings ReportMNKDMannKind3.4273 of 5 stars$3.96-2.5%$9.86+148.9%-31.5%$1.20B$297.60M39.60400Earnings ReportAnalyst ForecastAnalyst RevisionNVAXNovavax4.7101 of 5 stars$7.28-2.5%$15.86+117.8%-18.0%$1.18B$682.16M2.751,990News CoverageEarnings Report Related Companies and Tools Related Companies RGEN Competitors IONS Competitors MDGL Competitors ALKS Competitors LGND Competitors FOLD Competitors CLDX Competitors DVAX Competitors MNKD Competitors NVAX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
